All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
LONDON – Engitix Ltd has secured Takeda Pharmaceutical Co. Ltd.’s endorsement of its extracellular matrix (ECM) technology in a potential $500 million deal in liver fibrosis.
